Crossmark

Performance of MR fusion biopsy, systematic biopsy and combined biopsy on prostate cancer detection rate in 1229 patients stratified by PI-RADSv2 score on 3T multi-parametric MRI

Crossref DOI link: https://doi.org/10.1007/s00261-024-04753-3

Published Online: 2025-01-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Riskin-Jones, Hannah H.

Raman, Alex G.

Kulkarni, Rushikesh

Arnold, Corey W.

Sisk, Anthony

Felker, Ely

Lu, David S.

Marks, Leonard S.

Raman, Steven S.
License Information

Text and Data Mining valid from 2025-01-18

Version of Record valid from 2025-01-18
More Information

Article History

Received: 25 July 2024

Revised: 3 December 2024

Accepted: 5 December 2024

First Online: 18 January 2025

Declarations

:

: David Lu: Consultant, Medtronic plc Speaker, Medtronic plc Consultant, Johnson & Johnson Research Grant, Johnson & Johnson Consultant, Bayer AG Research Grant, Bayer AG Speaker, Bayer AG Leonard Marks: Founder, Avenda Health Steven Raman: Consultant, Johnson & Johnson Consultant, Bayer AG Consultant, Merck & Co, Inc Consultant, Amgen Inc Consultant, Profound Medical Inc.

Document is current

Any future updates will be listed below